Dispiro[cyclohexane-1,2'-[2H]indene-1'(3'H),2''-[2H]iMidazol]-4''-aMine, 4-Methoxy-5''-Methyl-6'-[5-(1-propyn-1-yl)-3-pyridinyl]-, (1α,1'R,4β)- manufacturers
- Lanabecestat
-
- $149.00 / 1mg
-
2026-01-04
- CAS:1383982-64-6
- Min. Order:
- Purity: 98.55%
- Supply Ability: 10g
|
| | Dispiro[cyclohexane-1,2'-[2H]indene-1'(3'H),2''-[2H]iMidazol]-4''-aMine, 4-Methoxy-5''-Methyl-6'-[5-(1-propyn-1-yl)-3-pyridinyl]-, (1α,1'R,4β)- Basic information |
| Product Name: | Dispiro[cyclohexane-1,2'-[2H]indene-1'(3'H),2''-[2H]iMidazol]-4''-aMine, 4-Methoxy-5''-Methyl-6'-[5-(1-propyn-1-yl)-3-pyridinyl]-, (1α,1'R,4β)- | | Synonyms: | CS-2359;Lanabecestat ( LY3314814, AZD3293);AZD 3293;LY3314814;AZD-3293;LY 3314814;AZD3293;Lanabecestat;Lanabecestat(AZD3293, LY3314814);Dispiro[cyclohexane-1,2'-[2H]indene-1'(3'H),2''-[2H]iMidazol]-4''-aMine, 4-Methoxy-5''-Methyl-6'-[5-(1-propyn-1-yl)-3-pyridinyl]-, (1α,1'R,4β)-;AZD3293 (LY3314814) | | CAS: | 1383982-64-6 | | MF: | C26H28N4O | | MW: | 412.53 | | EINECS: | 200-258-5 | | Product Categories: | | | Mol File: | 1383982-64-6.mol | ![Dispiro[cyclohexane-1,2'-[2H]indene-1'(3'H),2''-[2H]iMidazol]-4''-aMine, 4-Methoxy-5''-Methyl-6'-[5-(1-propyn-1-yl)-3-pyridinyl]-, (1α,1'R,4β)- Structure](CAS/20180808/GIF/1383982-64-6.gif) |
| | Dispiro[cyclohexane-1,2'-[2H]indene-1'(3'H),2''-[2H]iMidazol]-4''-aMine, 4-Methoxy-5''-Methyl-6'-[5-(1-propyn-1-yl)-3-pyridinyl]-, (1α,1'R,4β)- Chemical Properties |
| Boiling point | 621.9±65.0 °C(Predicted) | | density | 1.23±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO: soluble; Ethanol: soluble | | form | A solid | | pka | 4.60±0.60(Predicted) | | color | White to off-white |
| | Dispiro[cyclohexane-1,2'-[2H]indene-1'(3'H),2''-[2H]iMidazol]-4''-aMine, 4-Methoxy-5''-Methyl-6'-[5-(1-propyn-1-yl)-3-pyridinyl]-, (1α,1'R,4β)- Usage And Synthesis |
| Uses | Lanabecestat (AZD3293) is a potent, orally active and blood-brain barrier penetrating BACE1 inhibitor with a Ki of 0.4 nM. Lanabecestat is used for the research of Alzheimer's disease[1]. | | in vivo | In mice, guinea pigs, and dogs, lanabecestat displays significant dose- and time-dependent reductions in plasma, cerebrospinal fluid, and brain concentrations of Aβ40, Aβ42, and sAβPPβ[1]. | | IC 50 | BACE1 | | References | [1] Eketj?ll S, et al. AZD3293: A Novel, Orally Active BACE1 Inhibitor with High Potency and Permeability and Markedly Slow Off-Rate Kinetics. J Alzheimers Dis. 2016;50(4):1109-23. DOI:10.3233/JAD-150834 |
| | Dispiro[cyclohexane-1,2'-[2H]indene-1'(3'H),2''-[2H]iMidazol]-4''-aMine, 4-Methoxy-5''-Methyl-6'-[5-(1-propyn-1-yl)-3-pyridinyl]-, (1α,1'R,4β)- Preparation Products And Raw materials |
|